Antitrust Antitrust

In Zetia pay-for-delay suit against Merck, Glenmark, district court should mull efficiency of joinder, Fourth Circuit says

By Max Fillion
  • 04 Aug 2021 18:06
  • 04 Aug 2021 18:06
Merck and Glenmark have succeeded in their bid to have a federal appeals court decertify a class of plaintiffs accusing them of engaging in an illegal pay-for-delay deal insulating cholesterol drug Zetia from competition.

A three-judge panel on the US Court of Appeals for the Fourth Circuit today vacated a district court

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News